de Boer Daniel Anton Insider Trading Activity (PRQR)

Summary

Updated Jul 16, 2026

de Boer Daniel Anton has filed 2 SEC Form 4 filings across 1 company in the last 90 days — buying. Lifetime open-market purchases: $500K.

Profile

Daniel Anton De Boer (as listed in the SEC context) is the Chief Executive Officer of ProQR Therapeutics N.V. The most recent SEC filing provided is from 2026-07-08, which identifies him in the role of CEO at ProQR Therapeutics N.V. ProQR is a biotechnology company focused on RNA therapies. The SEC filing context does not provide additional public details about his prior positions, education, or other aspects of his background. The information available confirms his current leadership role but does not elaborate on early career history.

Role	Chief Executive Officer, Director
Notability	62/100

Board memberships

ProQR Therapeutics N.V.

Awards & honors

Serving as CEO of ProQR Therapeutics N.V. as of the 2026-07-08 SEC filing
Leading a publicly reported biotechnology company focused on RNA therapies

Recent Transactions

Date	Ticker	Company	Code	Shares	Price	Value
2026-07-13	PRQR	ProQR Therapeutics N.V.	P — Open-market purchase	150.0K	$1.74	$261K
2026-07-08	PRQR	ProQR Therapeutics N.V.	P — Open-market purchase	150.0K	$1.59	$238K

Frequently Asked Questions

Who is de Boer Daniel Anton?

How many SEC Form 4 filings has de Boer Daniel Anton submitted recently?

2 primary Form 4 filings in the last 90 days, covering 1 company.

Has de Boer Daniel Anton been buying or selling stock?

Recorded transactions: 2 open-market purchases ($500K) and 0 open-market sales () across all tracked filings.

Where can I see all of de Boer Daniel Anton's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

de Boer Daniel Anton — SEC Form 4 Insider Trading Activity